Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HS 20094

Next Previous
X
Search
Drug Profile

HS 20094

Alternative Names: HS-20094

Latest Information Update: 04 Dec 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Jiangsu Hansoh Pharmaceutical
  • Class Antihyperglycaemics; Obesity therapies
  • Mechanism of Action Gastric inhibitory polypeptide receptor agonists; Glucagon-like peptide-1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Obesity; Type 2 diabetes mellitus

Most Recent Events

  • 09 Sep 2024 Adverse events and efficacy data from a phase-II trial in Type 2 diabetes mellitus presented at the Annual Meeting of the European Association for the Study of Diabetes (EASD-2024),
  • 21 Jan 2024 Efficacy and adverse events data from a phase II trial in Type 2 diabetes mellitus presented at the 84th Annual Scientific Sessions of the American Diabetes Association (ADA-2024)
  • 16 Oct 2023 Phase-II clinical trials in Obesity (In volunteers) in China (SC) (NCT06118021)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top